Early research (Phase 1)WithdrawnNCT03982134What this trial is testingPDR001 + Panobinostat for Melanoma and NSCLCWho this might be right forMelanomaNon Small Cell Lung Cancer Muhammad Furqan
Testing effectiveness (Phase 2)Ended earlyNCT04455503What this trial is testingStudy of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1Who this might be right forMelanoma Stage IVMelanoma Stage III Evaxion Biotech A/S 15
Testing effectiveness (Phase 2)Active Not RecruitingNCT02743819What this trial is testingPembrolizumab and Ipilimumab After Prior Immunotherapy for MelanomaWho this might be right forMelanoma University of Chicago 70
Testing effectiveness (Phase 2)Ended earlyNCT05926960What this trial is testingA Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced MelanomaWho this might be right forMelanoma Pfizer 38
Testing effectiveness (Phase 2)UnknownNCT03917069What this trial is testingNab-PCE vs PC for MM After Failure of Anti-PD-1Who this might be right forAdvanced Melanoma Peking University Cancer Hospital & Institute 145
Early research (Phase 1)Study completedNCT03178851What this trial is testingCobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced MelanomaWho this might be right forMalignant Melanoma Hoffmann-La Roche 155
Testing effectiveness (Phase 2)Active Not RecruitingNCT05081609What this trial is testingInvestigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor MalignanciesWho this might be right forAdvanced Solid TumorLocally Advanced Solid TumorMetastatic Solid Tumor+10 more Ascendis Pharma Oncology Division A/S 320
Large-scale testing (Phase 3)Active Not RecruitingNCT05608291What this trial is testingA Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With SurgeryWho this might be right forMelanoma Regeneron Pharmaceuticals 1,564
Large-scale testing (Phase 3)Active Not RecruitingNCT02362594What this trial is testingStudy of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)Who this might be right forMelanoma Merck Sharp & Dohme LLC 1,019
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07615881What this trial is testingComparing Intravenous or Intradermal Administration of Anti-CTLA-4 in Combination With Anti-PD1 Treatment in Patients With MelanomaWho this might be right forMelanoma (Skin Cancer) Amsterdam UMC, location VUmc 18
Testing effectiveness (Phase 2)WithdrawnNCT03167177What this trial is testingQUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 TherapyWho this might be right forMelanoma ImmunityBio, Inc.